Investment Analysts’ Recent Ratings Updates for Zenas BioPharma (ZBIO)

Several brokerages have updated their recommendations and price targets on shares of Zenas BioPharma (NASDAQ: ZBIO) in the last few weeks:

• 1/6/2026 – Zenas BioPharma had its “buy” rating reaffirmed by analysts at Jefferies Financial Group Inc.. They now have a $48.00 price target on the stock.
• 1/5/2026 – Zenas BioPharma was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $19.00 price target on the stock, down previously from $37.00.
• 12/29/2025 – Zenas BioPharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Zenas BioPharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Zenas BioPharma had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $45.00 price target on the stock.
• 12/16/2025 – Zenas BioPharma had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 12/15/2025 – Zenas BioPharma had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/26/2025 – Zenas BioPharma is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $55.00 price target on the stock.
• 11/13/2025 – Zenas BioPharma had its price target raised by analysts at Morgan Stanley from $34.00 to $37.00. They now have an “overweight” rating on the stock.
• 11/8/2025 – Zenas BioPharma was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Insider Buying and Selling at Zenas BioPharma

In other Zenas BioPharma news, major shareholder Sr One Capital Management, Llc acquired 126,315 shares of the company’s stock in a transaction dated Thursday, October 9th. The shares were acquired at an average price of $19.00 per share, for a total transaction of $2,399,985.00. Following the acquisition, the insider owned 1,917,895 shares in the company, valued at $36,440,005. The trade was a 7.05% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Patrick G. Enright acquired 105,265 shares of the firm’s stock in a transaction that occurred on Thursday, October 9th. The shares were bought at an average cost of $19.00 per share, for a total transaction of $2,000,035.00. Following the acquisition, the director owned 1,832,669 shares of the company’s stock, valued at $34,820,711. This represents a 6.09% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 306,728 shares of company stock valued at $5,850,014 over the last ninety days. Corporate insiders own 16.50% of the company’s stock.

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.